Abstract: Autism is a neurodevelopmental disorder characterised by clinical, etiologic and genetic heterogeneity. It is often associated with other conditions, such as disorders of the CNS (tuberous sclerosis), developmental delay, attention deficit, epilepsy, and anxiety and mood disorders. Our survey found cytogenetically visible chromosomal anomalies in ~7.4% (129/1749) of autistic patients documented as well as several sub-microscopic variants. Almost every chromosome is affected by numeric or structural aberrations. Among the most consistent cytogenetics findings are fragile X and duplication of maternal 15q11-13. Molecular cytogenetics, together with genome scans and linkage/association studies, point to ≥22 chromosome regions harbouring putative autism susceptibility genes, such as 2q32, 3q25-27, 7q31-q35, 15q11-13, 16p13, Xp22, and Xq13. We hypothesise that there might be at least three types of autism susceptibility genes/mutations that can be (i) specific to an individual patient or family, (ii) in a genetically isolated sub-population and (iii) a common factor shared amongst different populations. The genes/mutations could act alone or interact with other genetic and/or epigenetic or environmental factors, causing autism or related disorders. This review emphasises the potential of analysing chromosomal rearrangements as a means to rapidly define candidate disease loci for further investigation. To facilitate ongoing research we have established a new database of autism-associated chromosomal anomalies (http://tcag.bioinfo. sickkids.on.ca/autism).
INTRODUCTION
Autistic disorder (AD, MIM 209850) is one of a spectrum of neurodevelopmental conditions, each characterised by significant impairments in social, communicative, and behavioural functioning. Collectively, this grouping is called the pervasive developmental disorders (PDD) [1] or the autism spectrum disorders (ASDs). The ASD's include atypical autism (also referred to as pervasive developmental disorder not otherwise specified, hence PDD NOS), Asperger's syndrome, and childhood disintegrative disorder. There is considerable clinical heterogeneity even among individuals with strictly defined autistic disorder, and numerous findings from family and genetic studies strongly implicate etiologic heterogeneity as well [2] . In some cases, autistic disorder can be associated with specific neurogenetic syndromes such as fragile X syndrome, untreated PKU, disorders of the CNS (tuberous sclerosis) and Prader-Willi/ Angelman syndrome (PWS/AS). As well, the clinical phenotype of autism and the ASD's often includes other symptoms, which are known to have a strong genetic component, including hyperactivity, language impairments and anxiety.
The reported prevalence of autism seems to have risen in recent years reflecting, in part, changes in diagnostic criteria, improved recognition of the disorder in clinical practice, and *Address correspondence to this author at McMaster University Medical Centre 3N14, 1200 Main St. W., Hamilton, Ontario, Canada, L8S 4J9; Tel: (905) 521-2100 Ext. 73715; Fax: (905) 521-2651; E-mail: xujie@hhsc.ca possibly actual increases [3, 4] . The most recent reviews estimate prevalence of AD at ~2-3 per 1000 children, and the prevalence of all PDDs as high as 6 or 7 per 1000 children [5] . Autism occurs predominantly in males with estimated male to female ratio of about 4:1 [6] .
Strong evidence of genetic influences in AD originated from twin studies that showed higher concordance rates for AD in monozygotic compared with dizygotic twins [7, 8] . Moreover, autism exhibits an approximate 90% heritability [9] and a recurrence risk in the 3-9% range [10] [11] [12] [13] [14] , the latter being considerably higher than population risk [4, 14] . Estimates of the number of genes range from 2-10 [15] to ≥15 [16, 17] to perhaps as many as 100 [18] . Recently, mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 were found associated with autism in a few rare cases [19, 199] and, if replicated, provide a precedent for identifying other contributing genetic factors [18] .
In this review, we have attempted to catalogue all chromosomal rearrangements associated with autism described in the literature or in public repositories or databases. Two independent researchers (J.X. and S.W.S.) performed systematic multiple keyword ("autism", "pervasive developmental disorder", "chromosome", "genome", " genetics" and "genomics") searches, scanning bibliography of retrieved papers for additional references, and search of public repositories. We read every paper and chapter including the relevant references and these datasets were then compared, contrasted, and eventually combined. Most of the cases used in these studies meet the diagnostic criteria outlined in DSMIII [20] , DSMIII-R [21] , DSM-IV [1] or ICD-10 research [22] . We recognise that including cases diagnosed using multiple versions of DSM criteria introduces additional heterogeneity, that there is very substantial overlap. We would lose important data if we chose to discard all cases diagnosed prior to 1994 when DSM-IV was first released. We also recognise another inherent limitation that most of the published papers have not applied standardised diagnostic measures ADI and ADOS and involved epidemiological samples. We hope that these issues are taken into consideration in future studies of genetics of autism. As this review was intended to facilitate the identification of chromosomal anomalies and regions/genes of possible interest for further analysis in autism, we chose a broader phenotype, including cases with autistic-like behaviour. Since it is possible that some or many of these chromosomal rearrangements may be randomly associated with autistic disorder, in order to further prioritise their relevance for candidate disease gene studies we also reviewed the data from family-based genetic studies to search for overlapping chromosomal intervals. We have created a database to house the chromosome rearrangement information, which will allow us to continue to collate information as it is made available to assist the autism research community.
CYTOGENETICS AND MOLECULAR GENETIC DETECTION OF CHROMOSOME REARRANGE-MENTS
It is difficult to obtain an accurate and reliable estimate of the prevalence of chromosomal anomalies in autism patients because literature surveys vary in the clinical criteria of diagnosis, sample size, and cytogenetic methods used (e.g. chromosome resolution, inclusion of sex chromosomes, chromosome fragility test, definition of chromosome anomaly). Recent studies which employ standardised diagnostic assessment tools and exclude children with profound intellectual disabilities [13] tend to identify a lower prevalence of cytogenetic abnormalities in autism compared to other studies using less rigorous diagnostic standards [23, 24] . Estimates from some studies may also be biased upwards by selective testing based on the presence of dysmorphic features and/or severe disability (e.g., Konstantareas & Homatidis, 1999) [25] . Nevertheless, 15 worldwide studies show that the mean rate observed is 7.4% (129/1749) with a range from 0-54% (see Table 1 ) (also see reviews [26] [27] [28] [29] [30] ). Almost every chromosome was found to be implicated; numerical or structural aberrations were all documented, including translocation, inversion, duplication, deletion, marker, ring, or mosaicism. Among the most frequent findings in (Table 1) are fra(X)(q27) (3.1%; 28/899) and anomalies involving proximal 15q (0.97%; 17/1749). It is interesting to note that 14 of the 129 abnormal cases are classic chromosome syndromes; 2 cases of 45,X, 2 cases of XXY, 2 cases of XYY, 7 cases of trisomy 21, and 1 case of trisomy 13. In addition, there are 22 cases (1.3%; 22/1749) of apparently balanced rearrangements (9 inversions and 13 translocations). Advances in molecular cytogenetics (e.g. FISH, spectral karyotyping, microarray-based comparative genomic hybridisation, genotyping, genome scan) have opened up a new avenue to characterise chromosomal anomalies not detected by routine methods, such as complex aberrations, submicroscopic or subtelomeric rearrangements, parent-of-origin of chromosome segment [31] [32] [33] [34] [35] [36] [37] .
CHROMOSOME FRAGILITY/FRAGILE X
The Fragile X at Xq27.3 (fra(X)) is the single most common chromosome anomaly associated with autism. The prevalence of autism among individuals with frag(X) syndrome ranged from 5-60% [28, 38] and conversely the frequency of frag(X) syndrome among individuals with autism varies from 0-20% [28] . The differences are likely due to variation in sample size, diagnostic criteria and method of fragility testing.
There are two possible explanations for the apparent association between frag(X) and autism. Until recently, the prevailing view was that frag(X) was a cause of autism in some individuals, and that Xq27.3 might harbour an autism susceptibility gene that was operant in other cases as well [24, 39, 40] . However, more recent data suggests that the relationship between frag(X) and autism is primarily due to a common association with MR [41] [42] [43] , and that specific behavioural symptoms (gaze aversion and hand flapping) that overlap between autism and frag(X) [28, [44] [45] [46] . Several molecular genetics studies have shown no evidence of linkage with markers on the X chromosome or at Xq27.3 and absence of fra(X) CGG repeat expansion in autistic patients [41, 42, [47] [48] [49] suggesting that the site does not contain a susceptibility gene. However, Yamagata et al. (2003) [50] reported 1/70 autistic patients had FMR1 repeat expansion. Notably, the use of standardised diagnostic measures (e.g., the Autism Diagnostic Observation Scale; Lord et al., 2001 [51] ) may help to distinguish true cases of autism from children with MR who have isolated behavioural features that overlap with autism.
To examine for a possible association of fragile sites and autism Arrieta et al. (2002) [52] applied two different statistical methods previously described to work with fragile sites (FSs) from pooled data [53] and from single individuals [54, 55] . The use of these two methods was intended to avoid identification of some false, "common", FSs. They found significant statistical differences in spontaneous expression of chromosome breakages between autistic patients and controls, with a minimal sex difference. Eight autosomal FSs had preferential expression in patients and 5 of 27 (18.5%) were positive at frag(X). The 8 autosomal FSs include 4 common FSs (3p14.2, 6p22.2, 16q23.2, and 18q12.2) and 4 rare FSs (2q22.3, 6p23, 10q23.3 and 22q13). Most of the FSs were previously reported in association with autism [23, 24, 27, 56, [58] [59] [60] . Of note, the locus 6p23 contains the gene responsible for spinocerebellar ataxia 1, a CAG repeat disease [57] and the FS at 22q13 is near NF2, a tumour suppressor gene responsible for neurofibromatosis.
DUPLICATION OF 15q11-q13
Proximal 15q is a hotspot for chromosome rearrangements, including deletion, duplication, or triplication of various genomic intervals. Instability of this region is usually mediated by low-copy repeated sequences called segmental duplications (or duplicons) [61] . High sequence identity between duplicons can facilitate mispairing and [37] .. unequal recombination events in meiosis and mitosis, which can result in chromosome imbalances. Deletion of 15q11-q13 is a hallmark for PWS/AS, depending upon the parentof-origin of the deletion. Dup(15q) can take the form of either intrachromosomal duplication or isodicentric 15q (also known as supernumerary chromosome, marker, tetrasomy of proximal 15q, or inv dup 15q). Based on parent-of origin and presence of Prader-Willi/Angelman critical region (PW/ASCR), cases of dup 15q reported to date can be categorised into three groups [62] [63] [64] [65] [66] [67] . The first group (25 cases) consists of patients with euchromatic variants of no clinical significance and without duplication of PW/ASCR [65, 68, 69] . The second group (16 cases) is comprised of patients with maternally inherited PW/ASCR duplication and clinical features including DD, MR, autism/atypical autism, learning/speech difficulties, but without consistent dysmorphic findings [62, 63, 70, 71] . The maternally-derived dup 15q is the most consistent anomaly associated with autism [72] . The third group (3 cases) include patients with paternally inherited duplication of PW/ASCR and with clinical findings varying from apparently normal [63] to significantly abnormal, including DD, communication disorder, depression, obesity and significant behavioural problems [65, 73] .
Identifying such inherited duplications has important implications for estimation of recurrence risk, which may rise from the empiric risk of 3-9% [10] [11] [12] [13] [14] to up to 50% for maternal duplication [66] . An accurate definition of these duplications requires a combination of high resolution Gbanding, FISH of probes specific to PW/ASCR, methylation and/or genotyping analysis. Of note, Thomas et al (2003) [67] cautioned that while FISH is informative in most cases, it could miss double signals or dup 15q, especially on shorter chromosomes. The authors suggest that molecular studies (e.g. tri-or tetranucleiotide analysis) are most accurate to assess the duplication status. Christian et al. (2003) [74] identified a maternal duplication of 15q in one autism patient by single nucleotide polymorphism (SNP) typing during linkage disequilibrium mapping exercise.
MONOSOMY X
Four cases of Turner syndrome with autistic disorder and a maternally inherited X chromosome have been documented. Skuse et al. (1997) [31] reported that the three Turner syndrome females with maternally inherited X chromosome had reduced social cognition scores compared with those with paternally inherited X chromosome. Based on this observation they suggest that there is genetic locus for social cognition that is imprinted and is not expressed from the maternally derived X chromosome. A case report by [75] further supports this hypothesis. Their finding that normal males with 46,XY and with the X chromosome being maternally derived had significantly reduced social cognition in comparison with normal female with 46,XX provides additional evidence to suggest that an imprinted gene on the X chromosome influences social competence. It was argued that although this imprinted gene alone might not cause autism, it might have a modifying effect on other genes that contribute to autistic disorder. Identifying the sites of action of this X-linked gene could lead to the discovery of autosomal genes that directly increase risk for autism [76] . There have been no reports of cases with paternally derived X chromosome and autistic behaviours.
APPARENTLY BALANCED REARRANGEMENTS
Balanced chromosome rearrangements are observed at a significantly increased rate (~1.3% see Table 1 ) in autistic patients compared to that observed in the general population (~4.3/1000) [77] . Of note, Castermans et al. (2003) [35] reported 4 of 525 subjects with idiopathic autism had de novo apparently balanced rearrangements (3 translocations and 1 paracentric inversion), which is much higher than would be expected from a general population (roughly 1/2,000 for a reciprocal translocation and 1/10,000 for a paracentic inversion [78, 79] ). This suggests that certain chromosome aberrations may act as susceptible factors for autism.
Until recently, inherited balanced rearrangements were generally felt to be clinically insignificant if the carrier parent (and/or relatives) were clinically normal. However, there are many reports of incomplete penetrance or variable expression of phenotype in such cases, which need to be considered before causation is ruled out. For an inherited or de novo, apparently balanced, rearrangement -associated with disease, four possibilities exist. 1) Random association.
2) The rearrangement is not truly balanced, with sub-microscopic aberrations such as deletion or duplication. 3) It is balanced, but the breakpoint disrupts a gene, leading to haploinsufficiency of the gene and protein product or abnormal gene function (e.g. a new fusion gene product). And 4) silencing gene via a position effect mutation (the change in the genomic context of the gene due to the rearrangement can lead to dysregulation of its expression). Table 2 summarises the characterisation of the breakpoints in 11 autism-associated cytogenetically balanced [87] inv(4)(p12p15.3)mat GABA(A) receptor genes at 4p12 Choufani et al. 2003 [197] AUST: autism susceptibility locus; BAC: bacterial artificial clone; bp: breakpoint; CFTR: cystic fibrosis gene; inv: inversion; mat: maternally inherited; PAC: P1-derived artificial clone; pat: paternally inherited; t: translocation 1: GRPR: gastrin-releasing peptide receptor gene; showing to escape X-inactivation; SDC2: Syndecan-2 gene. The translocation is found in 27-year-old female patient with multiple exostoses, autism, MR and epilepsy. The origin of the translocation is uncertain for father was deceased with karyotype unknown though her mother's karyotype was normal (Bolton et al. 1995 [179] ). The translocation is balanced without loss or gain of a single nucleotide at DNA level. The interpretation was that a dosage effect of GRPR and a position effect of SDC2 may contribute to the patients' phenotype. 2: The apparently balanced de novo inversion is found in a 31 month-old boy with DD and autism and no speech. 3: The translocation is seen in the patient with childhood-onset schizophrenia/autistic disorder. It is paternally inherited and cosegregates, among the carriers in the family, with other significant psychopathologies, including alcohol/drug abuse, severe impulsivity, paranoid personality and language delay. 4: The translocation is inherited from an unaffected mother. 5: The translcoation is found in a girl with autism but the carrier mother does not express the disease. 6: The translocation is seen in a boy with DD and autism. PAX3: paired box 3; MMP16: matrix metalloproteinase 16. 7: The translocation is found in monozygotic twin concordance for autism. The origin of the translocation is uncertain since the father was deceased with no karyotype available whereas the mother's karyotype was normal. 8: This translocation was found in a female with autism, epilepsy, delayed walking with mild residual ataxia, a history of behavioural regression, fluctuating liver function tests and mild cerebellar atropy. A2BP1: ataxin-2 binding protein-1. **note that while karyotype indicates 7q32 breakpoint the PAC identified to span the breakpoint maps to 7q34. All other data in the paper suggests the breakpoint is at 7q34 and not 7q32. [80] or A2BP1 at 16p13.3 [81] . Five breakpoints were located within and/or interrupting the following genes GRPR at Xp22.13 [82] , MMP at 8q21.2 [80] , RAY1/ST7 at 7q31 [83] , AUST2 at 7q11.2 [84] , and the neurobeachin gene at 13q13.2 [35] . Three breakpoints were found located in the vicinity of specific genes SDC2 at 8q22.1 [82] , CFTR at 7q31.3 [85] , and SSBP and T2R3 at 7q34 [86] (see Table 2 for clarification of band of chromosomal rearrangement). As well, 2 breakpoints contain genes and pseudo-genes for cytochrome P450 at 7q22 and transcribed regions at 7q31.2 [87] .
It is interesting to note that the de novo balanced t(5;13)(q12.1;q13.2) interrupts neurobeachin gene at 13q [35] ; this region is previously identified as a candidate region for autism [88] . The expression analysis indicates that neurobeachin plays an important role during brain development. Previously a number of candidate genes for autism have been suggested in genetic syndromes featuring additional physical anomalies or global DD. The relevance of these genes to the understanding of the pathogenesis of idiopathic autism is uncertain. The report by Castermans et al. (2003) [35] based on a patient with a de novo aberration and no MR or physical anomalies suggests that the neurobeachin gene is a strong candidate gene for idiopathic autism.
Recently, Scherer et al. (2003) [89] published a DNA sequence and medical annotation map of human chromosome 7, including fine mapping of translocation breakpoints from 3 autism patients (7q22.1, 7q31.2 and 7q31.3). The most interesting finding was that the breakpoint at 7q31.3 overlapped with a rearrangement from an unrelated patient diagnosed with speech and language disorder. The breakpoint was anchored to the sequences using data from Lai et al (2000) [90] . Both breakpoints were found to disrupt the same, apparently non-coding, RNA transcript (TCAG_4133353), which is composed of at least 5 exons spanning 288 kb and is not found in the mouse genome. In the second case, the translocation breakpoint was at 7q31.2 near FOXP2. Finally, the breakpoint at 7q22.1 mapped nearest to the neuronal pentraxin 2 (NPTX2) gene, which is thought to be involved in excitationory synaptogenesis and could be considered a functional candidate for autism. So far, no evidence of autism-specific variants in the balanced rearrangements described above has been observed in other autistic disorder families.
SUBTELOMERE REARRANGEMENTS
Chromosome subtelomeric regions are gene rich and thus rearrangements in these intervals can often have clinical relevance. The chromosome telomere is characterised by a lack of distinctive G-bands, and therefore, aberrations involving this region can be missed by routine cytogenetic analysis. Molecular cytogenetic studies show that subtelomeric aberrations are found in ~4.6% (range: 0.0-29.4%) of patients with idiopathic MR and/or dysmorphism [36, 91, 93] . Many cases of distal chromosome rearrangements (e.g. del(2)(q27), dup16p, or del(22)(q13)) are associated with ASD [94] [95] [96] [97] . Of ≥20 cases of distal del 22q reported, some are cryptic deletions that can only be identified by FISH using telomere specific probes (e.g. control probe for DiGeorge/VCFs region) [96, 98] . While the clinical picture of the del(22)(q13) is still emerging, the range of expression appears to include normal or advanced growth, significantly delayed speech, PDD traits, and minor facial dysmorphism. It has been suggested that patients with these clinical features be screened for 22q13 deletion [96] .
These findings raise questions about the prevalence of subtelomeric anomalies in autism. Three pilot studies using a complete set of telomeric probes for FISH screening in autism have been reported. Wolff et al. (2002) [34] identified one of 10 autism children with a deletion on 2q that was detected initially using Cytocell Chromoprobe-T system at locus D2S2986 and was subsequently confirmed using Vysis 2q probe (D2S447). The mother of this child had a normal high-resolution karyotype and a normal subtelomere FISH test, while the father was not available for testing. It is possible that the deletion 2q is paternally inherited or is a polymorphism, as is well documented [91] . However, based on the subtle cytogenetic difference between the two chromosome 2 homologues, they concluded that the 2q deletion by FISH is most likely due to the significant loss of 2q material. Medne et al. (2003) [99] reported that 1/108 autistic patients had unbalanced subtelomeric translocation der(18)t(13;18)(q34;q23) not detectable cytogenetically. Keller et al. (2003) [100] found none of the 49 children with ASD had subtelomeric anomalies in the FISH screening. These studies together yield a total detection rate of 2/257 (<1%) and seem to suggest limited clinical utility of subtelomeric analysis [100] . However, further studies with larger sample size and different detection methods (e.g. CGH microarray, genotyping, quantitative PCR) could help assess the significance of subtelomeric abnormalities in ASD.
MICRODELETIONS DETECTED AS MENDELIAN INCONSISTENCIES FROM GENOME SCANS
Through analysis of genome scan data and identified Mendelian inconsistencies, Yu et al. (2002) [33] detected several sub-microscopic deletions in 12 of 105 families having two or more sibs affected with autism and/or PDD. The deletions range in size from 5 to > 260 kb and involve four different sites on chromosomes 7p22, 7q21 and 8. One family had a complex deletion at marker D7S630; with two segments deleted (37 kb and 18 kb) and two retained (2836 kb and 38 kb). Three families had deletions at D7S517, with each family having a different deletion (96 kb, 183 kb, and >69 kb). Another three families had deletions at D8S264 (8p23), again each family with a different deletion (ranging in size from 5.9 kb to >260 kb). Five families had a 192 kb deletion at marker D8S272 (8q24). Of the four markers, three (D7S630, D7S517 and D8S264) were found in families with autism or PDD and not in control families, suggesting that these regions with deletions might harbour autismsusceptible genes. In addition, this study demons-trates that DNA polymorphism-based methods, such as genome scan can provide sensitive alternatives in detecting/ screening for chromosome rearrangements in autism.
Y-HAPLOTYPE
The male to female ratio in autism is 4:1, but may be even higher in children with less developmental delay, Asperger syndrome and those without physical or brain abnormalities [101, 102] . The reason for the male predominance is unknown. In a search for Y susceptibility gene(s), [102] studied Y chromosome haplotypes of 111 autistic subjects from France, Sweden and Norway. They found no significant difference in Y-haplotypes between the affected and control group, suggesting no Y chromosome effect in autism. CHROMOSOME ABERRATIONS UNLIKELY RELATED TO AUTISM Ogilvie et al. (2000) [103] found no deletion of 22q11.2 in a group of 103 subjects with a strict diagnosis of autism in absence of other indications. They suggest that testing for del(22)(q11.2) is unlikely to be necessary in these patients. Knowledge of chromosome rearrangements unlikely related to autism is useful since this information can help prioritise investigational studies by eliminating unnecessary, labour intensive and expensive tests.
CANDIDATE REGIONS/GENES
In addition to the cytogenetic and molecular genetic approaches to search for chromosome rearrangements in autism that are described above, various other mapping strategies have been used alone, or in combination, in an attempt to identify candidate genes for autism. These approaches include linkage analysis [104] , association study [105, 106] , DNA sequencing [107] [108] [109] , mutational analysis of candidate genes [110] , and genome scans [16, 88, [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] . Twelve genome scans (see Table 3 ), together with data from other methods, have pointed to chromosome regions/loci of interest in 1p, 1q, 2q, 3p, 3q, 4p, 4q, 5p, 5q, 6q, 7q, 8q, 11p, 12p, 13q, 15q, 16p, 17q, 19p, 19q, Xp and Xq (also see reviews [28] [29] [30] 122] ). So far no region has been unambiguously confirmed in all studies and no gene has been conclusively identified as autism susceptible locus. However, 2q, 7q, 15q, 17q, and Xq appear to be most likely to harbour regions/loci for autism, based on replication of findings. The finding of multiple candidate loci (and in some cases, linkage signals arising from subsets of sib pairs with particular phenotypic features) strongly implicates genetic heterogeneity in this complex disorder. The variability in findings across studies might have resulted from different sample sizes, marker sets, clinical criteria, statistical approaches, and molecular methods, as well as the tendency to report suggestive (but not necessarily statistically significant) findings. We describe the most relevant genetic mapping results below and comment if there is chromosome rearrangement data that implicates a common chromosomal region. Since this is a rapidly evolving dataset we encourage those interested to monitor the autism chromosome rearrangement database for new entries.
2q
Linkage to the long arm of chromosome 2 (2q) around q32 is observed in several genome scans [111-114, 117, 118] . IMGSAC (2001) [112] found that the most significant locus is at D2S2188 [206.4cM] [117] reported the linkage to the 2q region with MLS of 1.12 at D2S116 [198. 6 cM] in 99 affected families and the support for linkage increased to MLS of 2.86 and HLOD of 2.12 in 45 narrowly defined families with PSD. These reports provide further evidences that phenotypic homogeneity may increase the power to find susceptibility loci for autism (unless the variation in significance levels is the result of multiple testing). The report by Buxbaum et al (2001) [114] is particularly interesting, considering a finding by Szatmari et al. (2000) [2] that onset of phrase speech may be a crucial differential diagnostic feature within PDD.
Many cases of abnormal chromosome 2q are reported in autism, including distal deletion 2q37 [97, [123] [124] [125] [126] [127] , cryptic deletion of 2q35 in de novo translocation t(2;8)(q35;q21.2) [80] and de novo interstitial deletion del(2)(q32.1q32.2) or (q32.2q32.3) [128] . The latter case is particularly interesting; the 14-year-old boy is featured with a small chromosome deletion and no noticeable dysmorphic findings. ASD is his main clinical presentation. This case provides a strong cytogenentic support for the linkage to 2q32.
Several potentially relevant genes are located in the 2q region, including two Distaless class homeobox genes (DLX1 and DLX2), Alpha-1-chimaerin (a1CHIM) and the alternatively spliced a2CHIM, a GTPase-activating protein, T-box brain 1(TBR1), neuopilin (NRP2), camp response element-binding protein 1 and 2 (CREB1 and CREB2) [112] , glutamic acid decarboylase 1(GAD1), cAMP guanine nucleaotide exchange factor II(cAMP-GEFII), chimerin 1(CHN1), activating transcription factor 2)(ATF2), homeo box D1(HOXD1) and neurogenic differentiation 1(NEU ROD1). Bacchelli et al. (2003) [129] screened 9 candidate genes for autism on this 2q region: TBR-1, GAD1, DLX1, DLX2, cAMP-GEFII, CHN1, ATF2, HOXD1, and NEU ROD1. The screening for the DNA variants and association analysis using intragenic SNP provided no strong evidence that any of these genes plays a major role in aetiology of autism. However, they identified 4 rare non-synonymous variants in the cAMP-GEFII gene. These variants were present in 5 families, where they cosegregate with the autistic phenotype and were not seen in control individuals. Further studies are needed to study the significance of these variants. Based on evidence from molecular cytogenetics, exon screening and linkage studies, recently Wassink et al.(2003) [126] proposed the gene centaurin gamma-2 (CENTG2) located at 2q27.3 as an autism-susceptibility gene.
3q
Chromosome 3q25-q27 is identified by Auranen et al. (2002) [116] to harbour a new locus with a MLS of 4.81 in the vicinity of D3S3715/D3S3037 [190.4cM] . This is based on a two-stage genome scan of 38 Finnish families. This finding is supported by the suggestive association and skewing of the marker alleles in disease chromosomes from the genetically isolated Finnish sub-population from Central Finland. This result may facilitate the positional cloning of the susceptible gene. It remains to be seen if other populations share this locus, or if it is unique to the Finnish isolate. There are reports of individuals with autistic features and speech and language delay having a 3q25 deletion [57, 130] and inversion of 3q25-q29 [131] , respectively. [30] . HLOD: heterogeneity LOD; LOD: logarithm of the odds; MLS: maximum LOD score; MMLS/het: maximum multipoint heterogeneity LOD score; NPL: non-parametric linkage; XMLS: X-linked maximum LOD score.
6q
A genome screen by Philippe et al. (1999) [113] identified 6q21 to be the most significant region with a MLS score of 2.23 at D6S283, which is located within intron 11 of glutamate receptor 6 gene (GluR6 or GRIK2). In a follow-up study using a larger number of autistic patients (227 children; 59 ASP and 107 trios) and two different methods (sib-pair analysis and TDT), [132] found significant linkage between the GluR6 and autism. The authors suggested that GluR6 or a nearby gene might be implicated in the predisposition to autism. Interestingly, these findings contrast with other genome screens, which have not yielded significant linkage to 6q16-23. Replication tests in other samples, meta-analysis or functional studies are needed to determine the potential role of GluR6 in the etiology of autism. While there are chromosome 6 anomalies associated with autism at the time of writing, none overlapped with the regions mentioned above. 7q31-q35 appears to be one of the strongest candidate regions in autism. The maximum evidence for linkage is in the 103-129 cM region as suggested by positive findings from several genome scans [111] [112] [113] 118] . Peak MLS scores of 2.53 for marker D7S530 [111] , MMLS of 3.20 for D7S477 [112] , MLS of 1.66 for D7S495 [118] , and MMLS of 2.44 between D7S530 and D7S640 [133] . IMGSAC [112] characterised an autism susceptible locus (AUST1) overlapping a 27 cM region on 7q, inclusive of the FOXP2 locus (forkhead box P2, also known as SPCH1) [90] . Hutcheson et al. (2003) [134] examined the CLSA (1999) [ 88] dataset using recombination breakpoint analysis and narrowed a minimum candidate region to between D7S496 and D7S2418 (120-123 cM) encompassing ~4.5 Mb of genomic DNA containing over 50 genes. As previously stated, chromosomal microdeletions of marker D7S630 at 7q21close to the region with maximum evidence for linkage, was observed only in the families with autism or PDD and not in control families [33] . Another linked region with a MLS of 3.66 at D7S2462 at 7q36.2 was suggested [116] based on a genome scan of 38 Finnish families, an association study and a gamete competition test. The marker D7S2462 is ~58cM telomeric from the AUST1 locus and 4.6 cM from D7S483, a marker [115] with MLS of 2.13 with 110-sib-pair families with a broad phenotype (Autism, Asperger syndrome, or PDD). A regional meta-analysis of four genomewide scans found that the only significant replication in multiple scans is at 7q [135] .
Several cytogenetics reports involving 7q provide supportive evidence as described earlier. Ashley-Koch et al. (1999) [104] reported 3 siblings with maternally inherited inversion, inv(7)(q22q31.2); two (male) children had AD and the 3rd child (female) had significant DD and expressive language disorder. An update of this study indicates that the proximal breakpoint is found at the P450 cytochrome oxidase cluster of genes and the distal breakpoint in a 175 kb region at 7q31 [87] . It was found that cosegregation of mutations in the FOXP2/SPCH1 gene at 7q31 with a severe speech and language disorder (but without ASD) in a threegeneration pedigree [90, 136] . Warburton et al. (2000) [85] reported two unrelated individuals; one with AD and another with specific language impairment (SLI) and both had chromosome rearrangements involving 7q31.3, one of which was ultimately found to interrupt the FOXP2 gene [90] . The second breakpoint in this study was in fact also characterised by Lai et al. (2000) [137] and as was mentioned earlier found to interrupt the non-coding RNA transcript TCAG_4133353) [89] . There are additional case reports of translocations involving 7q31.3 [32] and 7q34 [86] ( Table  2) .
More than a dozen of candidate genes located in the 7q have been examined by molecular analysis because of their proximity to chromosome rearrangements and/or regions implicated by genetic analyses. While there are some interesting findings, no conclusive evidence of an autismspecific mutation has been identified. RAY1 (also known as ST7, suppression of tumourigenicity 7) is interrupted by a translocation breakpoint at 7q31.3 in an autism patient [32, 83] . Screening of the exons of the RAY1/ST7 in 90 unrelated autism probands identified several rare sequence variants. While these variants were not found in control population, it is unclear whether they contribute to the autistic pheontype [83] .
WNT2 (Wingless-type MMTV integration site family member 2) the gene adjacent to RAY1 was reported to influence genetic risk in autism [138] . WNT2 is one of a dozen WNT genes encoding secreted growth factor-like proteins that participate in growth, regulation, differentiation and tumourgenesis. McCoy et al. (2002) [139] failed to find a significant association between autism and WNT2 genotype in either the overall dataset or in the languageimpaired subset of families. RELN (reelin) is implicated in autosomal recessive lissencephaly with cerebellar hypoplasia [140] . It plays a pivotal role in the development of laminar structures including the cerebral cortex, hippocampus, and cerebellum and of several brainstem nuclei [109] . Persico et al. (2001) [109] found a significant association between AD and a polymorphic GGC repeat located immediately 5' of the RELN ATG initiator codon, as well as with specific haplotypes formed by this polymorphism with two singlebase substitutions located in a splice junction in exon 6 and within exon 50. They suggest that longer triplet repeats in the 5'UTR of the RELN gene confer vulnerability to AD. However, this association was not replicated in other studies [141, 142] . CORTBP2 (Cortactin-binding protein-2) is a gene of 5975 bp in size with 23 exons and is located ~45 kb telomeric to CFTR at 7q31.3 [143] . It was expressed at highest levels in the brain and was suggested a positional candidate for AUST1 but the mutational analysis did not reveal disease-specific variants [143] .
CADPS2 is proposed to act as a calcium sensor in constitutive vesicle trafficking and secretion [144] . It spans 561 kb at 7q31.3. The function, expression profile and location of CADPS2 made it a candidate gene for autism, however, no diseases-specific variants were identified in mutation screening for all 28 exons in 90 unrelated autism patients [144] .
FOXP2 is a large gene with some isoforms spanning greater than 600 kb [145] and it is expressed in the brain [146] . It was the first gene shown to be involved in speech and language ability [90] . The FOXP2 was disrupted by a translocation breakpoint in autism patients [137] . The findings raised the possibility that autism and severe language impairment and/or specific language impairment (SLI) might share a locus in the 7q region. No evidence of linkage or association of FOXP2 to SLI and/or autism has so far been found [147] [148] [149] [150] [151] . Of particular interest, O'Brien et al. (2003) [150] reported that no mutation was found in exon 14 of FOXP2 in 96 subjects with SLI, but strong association was detected with a marker within the CFTR gene and another marker on 7q31, D7S3052 (121cM), both adjacent to FOXP2. They suggest that genetic factors for regulation of common language impairment reside in the vicinity of FOXP2.
EN2 (homeodomain transcription factor ENGRAILED 2) located at 7q36.3 shows a significant association with ASD based on transmission/disequilibrium test and haplotype analysis of two intronic SNPs and haplotype analysis [152] . However, this finding was not replicated in another association and linkage study [153] .
Six additional genes, CULT1, SRPK2, SYPL, NrCAM, LAMB1 and PTPRZ1, with a role in brain development and function were recently studied (133] . Among the most interesting findings are an amino acid deletion in homeobox domain of CULT1 and 3 missense changes in LAMB1. The roles of these sequence variants in autism are under investigation.
15q
Several lines of evidence suggest that 15q11-q13 should be considered a candidate region harbouring AD susceptibility genes. This region contains the loci for PWS/AS and a subset of these patients have behavioural characteristics similar to that seen in AD [154] [155] [156] [157] [158] . As previously stated, many cytogenetic rearrangements involving 15q11-q13 have been documented in autism and 1% of individuals with AD or other PDD's have dup 15q11-13 [72, 159] . Moreover, several genome scans have identified 15q11-13 as a potential (albeit weakly contributing) susceptibility interval [16, 113, 115] .
Linkage and/or association studies implicate several candidate genes located at the 15q, including GABRB3, GABRA5 and the GABA γ genes (GABRG1, GABRG2 and GABRG3) [119, [160] [161] [162] [163] [164] . In addition, two other genes APBA2 [165] ] and UBE3A [166] are located in this region and are proposed as candidate loci. APBA2 (amyloid precursor protein-binding protein A2; also termed Mint2) is duplicated in some cases of autism. The gene is expressed throughout the central nervous system in the adult human and mouse and developing mouse embryo. It is considered an attractive positional candidate gene for involvement in duplication-associated and inherited autism. APBA2 is previously localised to the distal portion of the common PWS/AS deletion region and is recently mapped to 15q13.1 [165] . This represents a more telomeric location than reported previously, but is within a region duplicated in idic(15) marker chromosomes [165] .
UBE3A (E6-AP ubiquitin-protein ligas gene or Angelman gene), which is imprinted, affecting paternal silencing in brain, affects neurological function and learning. Recently, Sahoo et al. (2003) [166] proposed a mixed epigenetic-genetic model for autism with UBE3A as a principle candidate gene. They hypothesised that overexpression of an imprinted gene in 15q11-q13 is the major cause of autism and that UBE3A would be the strongest candidate with brain-specific failure of paternal silencing as a major mechanism. Amongst a subset of AGRE and NIMH autism sib-pairs they identified a small number of families with maternal duplication of the 15q. Genotyping of affected sib-pairs showed increased sharing of paternal alleles in the 15q region, with the greatest sharing centromeric to the imprinting centre at D15S817. They proposed that in the majority of cases autism is caused by imprinting defects arising on normal or susceptible paternal chromosome 15 during spermetogenesis or after fertilisation prior to MZ twinning, leading to brain-specific over-expression of UBE3A.
16p
Four genome scans [111] [112] [113] 115 ] demonstrated some evidence for linkage between markers at 16p13 and autism. A partial trisomy 16p was reported in a patient with autistic disorder and Tourette's syndrome [95] . Among genes located in this region are N-Methyl-D-aspartate receptor (NMDA), tuberous sclerosis 2 (TSC2); a gene for one of the netrins (NTN2L), the CREB-binding protein (CREBBP), polycystic kidney diseases 1(PKD1), α-globin genes (HBA1 and HBA2).
17q
Two genome scans [112, 121] indicate linkage to the same region of chromosome 17q at 45-52 cM, in the general vicinity of the serotonin transporter (5-HTT; (SLC6A4).) and neurofibromatosis Type 1 (NF1) gene loci. The serotonin transporter has been suggested to be a candidate gene for autism [167] [168] [169] . The neurofibromatosis type 1 gene (NF1 at 17q11.2)/disorder is also reportedly associated with ASD in 85 patients from France [170] . However, this association was not evidenced in a replication study with more than 200 patients from South Carolina [171] . The finding that a large proportion of NF1 mutations can be complete deletion of the gene [172] [173] [174] [175] , as well as chromosome breakpoints in neuroblastoma being mapped distal to the NF1 coding exons [176] suggest this locus may have complex regulatory elements that should be studied further with respect to the NF1/autism association.
X
A contribution of the X-chromosome to autism is suggested by several findings including 1) an excess of affected males, 2) a trend for X chromosome skewing in autism group observed in one study [184] , 3) increased cooccurrence of autism and X-chromosome anomalies (e.g. fragile X), 4) the results of three genome scans, and 5) mutation screening studies of the NLGN3 and NLGN4 genes. While reports on significance of X-chromosome in autism remain controversial, it seems possible that a subset of autistic families are X-linked [177, 178] . Notably, two regions, Xp22 and Xq13 appear most likely to be implicated.
Xp22 is implicated by 5 cytogenetic cases and several molecular analyses. The 5 cytogenetics cases include one translocation t(X;8) with a breakpoint interrupting GRPR (cM19) at Xp22.1 [82, 179] , one case of a Xp22 duplication involving the STS locus and possibly ZFX locus [180, 181] , and three cases of de novo Xp22.3 deletion [181] . Association of autism and ARX gene mutation linked to Xp22.1 was also reported [182, 183] . Interestingly, a frameshift mutation (1186insT) in the neuroligin NLGN4 gene at Xp22.3 was found in two affected brothers (one with typical autism and another with Asperger's syndrome) in a Swedish family. The mutation is not found in an unaffected brother or in 350 unrelated controls (250 females and 100 males) [19] . More recently Laumonnier et al. (2004) [199] reported the presence of a 2 bp deletion in the NLGN4 in a large French family including members affected by nonspecific X-linked MR, with or without autism or PDD in affected male patients. This mutation leads to a premature stop codon in the middle of the sequence of the normal protein and is thought to suppress the transmembrane domain and sequences important for the dimerisation of neuroligins that are required for proper cell-cell interaction through binding to beta -neurexins. The finding of this mutation in both autistic and nonautistic MR males suggests that the NLGN4 involves not only autism, but also MR and that some types of AD and MR may have common genetic origins [199] .
The Xq13-q26.1 region was highlighted in three genome scans with the evidence of linkage to the markers DXS1047 (MLS 2.67) [115] , DXS6789 (MLS2.54) [118] and DXS7132 (MLS2.75) [116] . However, a recent finding by Jamain et al. (2003a) [19] points to Xq13 since a mutation (C->T transition) in neuroligin NLGN3 at Xq13 was found in 2 affected brothers (one with typical autism and another with Asperger syndrome) in a second Swedish family. The equivalent sequence variant was not found in 200 control samples [19] . It was hypothesised that a defect in NLGN3 or NLGN4 may abolish formation, stabilisation, or recognition of specific synapses essential for the communication processes [19, 199] . It is worth noting that Talebizadeh (2003) [184] failed to find mutations in NLGN3 and NLGN4 so other studies will be required to determine the extent of contribution of NLGN3 (and NLGN4) to autism.
FUTURE DIRECTIONS IN CLINICAL AND DIAGNOSTIC RESEARCH
A variety of inherited and de novo chromosomal rearrangements have been reported in autistic individuals, which suggest that in at least some cases (e.g. chromosome 15) dosage effects of defined genes can contribute to the phenotype. More recent studies implicating the NLGN3, NLGN4, and potentially MeCP2 [92, 185] in autism demonstrate that mutations in single gene can lead to all of the classic features of autism. In some cases it will be expected that specific mutations or genes will only be found in defined genetically isolated group such as the case in the study of a Central Finnish subpopulation [116] . In the remaining cases the mutations or polymorphisms may be more common within susceptibility genes such as the suspected loci mapped on chromosome 7 and 17. In these latter instances the study of chromosome rearrangements promises to offer one avenue to speed the cloning of causative genes as was recently accomplished for a dyslexia predisposition gene [186, 187] .
It is intriguing that approximately 7.4% of autistic patients have chromosome anomalies (Table I) . These findings emphasise that cytogenetics and molecular cytogenetics should be an essential part of comprehensive investigations. However, as has been pointed out in studies of mental retardation and malformation syndromes [93] the relatively high frequency should be interpreted with caution for various reasons. Firstly, the cases chosen for karyotyping may have been preferentially selected because of a more complex behavioural and/or physical phenotype. Secondly, a reporting bias may influence the studies showing a low yield, which would then be less likely to publish. Nevertheless, detecting a chromosome rearrangement in an autism patient can be used to differentiate idiopathic autism from chromosome syndromes. The surprising number of rearrangements suggest that perhaps autism is the final common pathway of many genes that, when dysregulated, lead to a non-specific and wide spread brain damage [188] .
The increasing availability of informative genetic testing, and greater sensitivity of molecular and cytogenetic testing may eventually serve to identify specific genetic factors in a significant proportion of individuals with ASD, possibly with differences in symptoms, treatment response and overall prognosis. Hence, genetic testing may ultimately assist with the clinical management of ASD. Equally important, further clarification of genetic mechanisms and biochemical pathways may also help identify new and more effective treatment strategies. In saying this, however, we are likely far from a simple biomarker-based diagnostic test for autism (i.e., a test that confirms the diagnosis of autism when positive), due to the complexity and apparent heterogeneity of the underlying genetic mechanisms. If we are able to identify genes that modify the risk of autism, then predictive genetic testing will likely become a viable option. Such testing may be particularly helpful for at-risk groups such as siblings and other relatives, and combined with efforts to identify early behavioural markers [189] , may allow earlier initiation of intervention than is currently possible. Notably, predictive genetic testing is currently available for other etiologically complex neurological disorders such as Alzheimer's disease. By consistently following more rigorous diagnostic practices, including the use of standardised assessment tools, we can more accurately determine rates of cytogenetic abnormalities in autism/ASD. Conversely, molecular and cytogenetic studies may help identify genetic subgroups with less clinical heterogeneity, which may guide future diagnostic classification systems.
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